Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE

Summary

Numerous human cardiac stem cell studies have been published, including relatively small number of patients. Meta-analysis of randomized trials have reported safety and a 3-6% increase in global left ventricular performance after intracoronary stem cell therapy in patients with acute myocardial infarction. Since most of the studies used different type of stem cells, delivery modes, and patient population, the results are heterogenous, therefore the comparison of the results is biased regarding generalizable conclusions about the effect of treatment. The present comparative meta-analysis is based on individual patient data, and gathers and pools the raw data, and analyzes the clinical outcome, safety and efficacy of the cardiac stem cell therapy.

Conditions

• Ischemic Heart Disease

Interventions

OTHER

cell therapy

Sponsors & Collaborators

• Nantes University Hospital

  collaborator OTHER

• Oslo University Hospital

  collaborator OTHER

• Medical University of Silesia

  collaborator OTHER

• Hannover Medical School

  collaborator OTHER

• VZW Cardiovascular Research Center Aalst

  collaborator OTHER

• Cedars-Sinai Medical Center

  collaborator OTHER

• Johann Wolfgang Goethe University Hospital

  collaborator OTHER

• University of Ulm

  collaborator OTHER

• Military Medical Academy, Belgrade, Serbia

  collaborator OTHER

• Novosibirsk Scientific Research Institute for Circulatory Pathology

  collaborator OTHER

• Rigshospitalet, Denmark

  collaborator OTHER

• Asklepios Kliniken Hamburg GmbH

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• University of Debrecen

  collaborator OTHER

• University of Targu Mures, Romania

  collaborator OTHER

• University Clinic for Cardiology, Skopje, Republic of Macedonia

  collaborator UNKNOWN

• State Health Center, Hungary

  collaborator OTHER

• Karolinska Institutet

  collaborator OTHER

• University of Zurich

  collaborator OTHER

• University of Oulu

  collaborator OTHER

• Odense University Hospital

  collaborator OTHER

• Minneapolis Heart Institute

  collaborator OTHER

• The University of Texas Health Science Center, Houston

  collaborator OTHER

• Klinik Hirslanden, Zurich

  collaborator OTHER

• University Hospital, Toulouse

  collaborator OTHER

• Heinrich-Heine University, Duesseldorf

  collaborator OTHER

• Medical University of Vienna

  lead OTHER

Principal Investigators

• Mariann Gyongyosi, MD · Medical University of Vienna

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-11-30

Primary Completion

2020-12-31

Completion

2020-12-31

Countries

• Austria

Study Locations